PDCD1 and cutaneous squamous cell carcinoma: Despite cutaneous squamous cell carcinoma (CSCC) being the second most common skin cancer worldwide, there were no approved systemic therapies for patients with unresectable and/or metastatic disease prior to the advent of anti-programmed cell death protein-1 (anti-PD1) agents cemiplimab and pembrolizumab [1,2].